Albireo Pharma, Inc.
ALBO · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $8 | $7 | $33 |
| % Growth | 19.8% | 20.1% | -79% | – |
| Cost of Goods Sold | $1 | $1 | $0 | $1 |
| Gross Profit | $9 | $7 | $7 | $32 |
| % Margin | 93.8% | 90.5% | 96.6% | 97.2% |
| R&D Expenses | $23 | $23 | $22 | $21 |
| G&A Expenses | $0 | $0 | $0 | $32 |
| SG&A Expenses | $21 | $22 | $17 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $7 | $3 |
| Operating Expenses | $44 | $45 | $46 | $43 |
| Operating Income | -$35 | -$37 | -$40 | -$11 |
| % Margin | -352.5% | -453.4% | -579% | -35.3% |
| Other Income/Exp. Net | -$3 | -$3 | -$3 | -$3 |
| Pre-Tax Income | -$38 | -$40 | -$42 | -$15 |
| Tax Expense | $1 | $3 | $3 | -$4 |
| Net Income | -$38 | -$43 | -$45 | -$11 |
| % Margin | -390.7% | -520.3% | -663.2% | -33.7% |
| EPS | -1.95 | -2.18 | -2.34 | -0.57 |
| % Growth | 10.6% | 6.8% | -310.5% | – |
| EPS Diluted | -1.95 | -2.18 | -2.34 | -0.57 |
| Weighted Avg Shares Out | 20 | 20 | 19 | 19 |
| Weighted Avg Shares Out Dil | 20 | 20 | 19 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$35 | -$37 | -$39 | $8 |
| % Margin | -357.5% | -452.3% | -577.3% | 25.9% |